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Current controversies in the management 
of aortoiliac occlusive disease 
Dav id  C. Brewster ,  MD, Boston, Mass. 
The numerous options currently available for treatment of  aortoiliac occlusive disease 
have led to considerable controversy in regard to the optimal method of  revascularization 
in Such patients. Differences of  opinion exist not only with respect to certain technical 
aspects of  direct anatomic aortic reconstruction, which has traditionally been regarded as 
the "gold standard" treatment, but even more importantly as to whether alternative 
methods including a variety of  catheter-based endoluminal therapies and extraanatomic 
grafts may offer nearly equivalent results with less risk and possible cost advantages. 
Although little truly definitive data is available, a review of  published information can 
help clarify many of  these management dilemmas. In the final analysis, the various 
methods may not be as competitive with one another as first seems apparent. Each has its 
own specific advantages and disadvantages and when used, in appropriate circumstances 
can provide excellent results. Indeed, it is this broad spectrum of  options that can be 
matched to each patient's own unique anatomic and risk characteristics that make 
treatment of  aortoiliac disease one of  the most successful areas of  contemporary vascular 
surgery practice. (J Vase Surg 1997;25:365-79.)  
The infrarenal abdominal aorta and iliac arteries 
are among the most common sites of chronic athero- 
sclerosis in patients with symptomatic occlusive dis- 
ease of the lower extremities? Because arteriosclero- 
sis is frequently a generalized process, obliterative 
disease in the aortoiliac segment frequently coexists 
with disease below the inguinal igament. 2 Despite its 
widespread nature, however, aortoiliac disease is usu- 
ally segmental in distribution and therefore amenable 
to effective treatment. Even in patients with multi- 
level disease successful correction of hemodynami- 
cally significant inflow disease will frequently provide 
adequate revascularization f  the extremities and sat- 
isfactory clinical relief ofischemic symptoms. Careful 
assessment of the adequacy of arterial inflow is also of 
crucial importance, even in patients whose principal 
disease is infrainguinal in location, to ensure that 
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effective and durable results of distal arterial recon- 
struction are obtained. For all of these reasons man- 
agement ofaortoiliac disease is an important compo- 
nent in the day-to-day clinical practice of all vascular 
surgeons. 
In the 5 decades that have elapsed since the 
introduction of initial methods of revascularization 
by means of homografts and endarterectomy, 3-s a 
wide variety of therapeutic options have been devel- 
oped and advocated for management of aortoiliac 
disease. These can be broadly categorized as ana- 
tomic or direct reconstructive procedures on the 
aortoiliac vessels, so-called extraanatomic or indirect 
bypass grafts that avoid normal anatomic pathways, 
and various nonoperative catheter-based ndolumi- 
nal therapies that emphasize treatment of occlusive 
lesions by a remote, often percutaneous access ite to 
the arterial system. Although the availability of these 
numerous alternative therapies i certainly beneficial, 
enabling the surgeon to select a procedure appropri- 
ate to the individual anatomy and risk status of each 
patient, decision making is frequently complex and 
difficult. Substantial differences in reported early and 
late results of alternative methods have contributed 
to confusion. Purported benefits and advantages, 
particularly of endoluminal techniques, have been 
accentuated in recent years by the explosive growth 
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of cost and length-of-stay considerations and the 
implication by some that less invasive treatment is
inherently superior. Indeed, optimal management of 
aortoiliac disease represents one of the most contro- 
versial areas of contemporary vascular surgery prac- 
tice. 
In reviewing available data regarding such con- 
troversies, I would like to focus on several major j 
questions. First, what are the optimal methods of 
anatomic aortic surgical reconstruction? Certain 
technical controversies persist regarding aortob- 
ifemoral (ABF) bypass, which is generally accepted as 
the conventional method of choice for correction of 
aortoiliac disease. Second and likely most important 
is the controversy regarding the r cent claims that 
alternative methods ofrevascularization may provide 
results equivalent to ABF and should therefore be 
more widely used. Implicit in this viewpoint is the 
belief that if one accepts equivalent efficacy and dura- 
bility of alternative methods f revascularization, the 
perceived cost and safety advantages of these tech- 
niques should lead to a marked reduction or even 
elimination of conventional ABF graft procedures. 
It is important to emphasize at the onset hat few 
truly definitive data on these topics exist. There are 
few prospective randomized comparative studies 
with adequate control of the complex variables in- 
volved. Personal bias, previous urgical training, and 
previous individual experience remain important fac- 
tors in decision making. In addition, the need to 
individualize each decision as dictated by specific 
anatomic distribution of disease and operative risk 
considerations unique to every patient means by def- 
inition that there is not a single optimal procedure. 
The best procedure will and likely should vary from 
patient o patient. 
AORTOBIFEMORAL GRAFTING 
Since the pioneering development of a fabric ar- 
terial graft by Voorhees 6 and initial use of prosthetic 
aortic grafts in the [[950S, 7'8 extensive clinical experi- 
ence has clearly established ABF as the gold standard 
in the treatment of aortoiliac disease. Subsequent 
refinements in operative t chniques, improvement in 
prosthetic graft and suture materials, and in particu- 
lar striking advances in preoperative evaluation, in- 
traoperative anesthetic management, and postopera- 
tive supportive care have all contributed to steadily 
improving outcome and generally excellent results 
attainable in current contemporary practice. 9-i5 The 
major reasons for the primary role of ABF are its 
well-documented durability (long-term patency), su- 
perior functional results (hemodynamic mprove- 
ment, symptom relief, and limb salvage), and wide 
applicability to most patterns of aortoiliac disease. 
Principal emphasis is appropriately placed on long- 
term patency rates of 85% to 90% at 5 years and 75% 
to 80% at 10 years, results unmatched by other meth- 
ods. In current practice elective mortality rates of 
approximately 1% to 2% in appropriately selected 
patients with low early and late complication rates are 
currently obtained at many experienced centers. For 
all of these reasons the results of ABF are indeed the 
yardstick with which competitive methods of revas- 
cularization must be justifiably compared. 
Although the indications for and basic principles 
of ABF have become fairly standardized and well 
accepted, ifferences of opinion persist regarding cer- 
tain technical aspects of the procedure, and some 
remain topics of intense debate. 
Endarterectomy versus grafting. Although 
aortoiliac endarterectomy was frequently used in the 
early era of aortic reconstruction, 16-i8 it is rarely used 
by most vascular surgeons in current practice. The 
principal potential benefit of endarterectomy is 
avoidance of the use of prosthetic grafts, with their 
possible complications of dilation, infection, anasto- 
motic aneurysm, or other degenerative problems. 
However, these are all fortunately relatively unusual 
problems, especially with the improved quality of 
modern vascular grafts. Endarterectomy is also advo- 
cated by some as more likely to improve sexual po- 
tency in male patients by more effectively improving 
hypogastric artery blood flow. However, this has not 
been demonstrated in any study, and the more exten- 
sive dissection in the region of the aortic bifurcation 
required in endarterectomy seems likely to result in a
higher incidence ofneurogenic problems and ejacu- 
latory disturbance. 
Endarterectomy ay be used for localized isease 
confined to the digtal aorta, aortic bifurcation, and 
common ifiac arteries. In such patients the long-term 
patency is excellent and equivalent to that of graft 
procedures. 9,18-2° However, it has been well docu- 
mented that more extensive ndarterectomy extend- 
ing into the external i iac arteries or beyond oes not 
have the same durability and patency as bypass graft- 
ing. 9,21,22 Because localized aortoiliac disease most 
amenable to endarterectomy is encountered in only 
5% to 10% of patients requiring aortic reconstruc- 
tionfl the vast majority of patients with more xten- 
sive disease are not suitable for endarterectomy and 
will be better treated by graft insertion. 
In addition, in the last decade use of percutane- 
ous transluminal angioplasty (PTA), atherectomy, 
stent insertion, and other endoluminal procedures 
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for relatively localized aortoiliac disease has further 
encroached on cases formerly considered for possible 
conventional endarterectomy. Finally, endarterec- 
tomy is acknowledged to be a technically demanding 
procedure. Although a few centers continue to per- 
form an adequate number of aortoiliac endarterec- 
tomy procedures for trainees to feel comfortable with 
the technique, most vascular surgeons trained within 
the past decade will have little to no training and 
experience with this method. 
For these reasons bypass grafting has become the 
standard method of direct surgical repair for occlu- 
sive disease in almost all patients. ABF grafts offer the 
most durable and expeditious reconstruction avail- 
able. Endarterectomy remains possibly useful for a 
small number of patients with localized disease, par- 
ticularly very young patients with an expected life 
span 0f20 to 30 years in whom a higher incidence of 
possible graft-related problems might be anticipated 
or in patients who may have an increased risk of 
infection with a nonautogenous reconstruction. 2a 
Proximal anastomosis: end-to-end versus end- 
to-side. The best configuration of the proximal 
graft anastomosis remains one of the most unsettled 
and hotly debated issues among vascular surgeons. 
End-to-end anastomosis i clearly indicated in pa- 
tients with coexisting aneurysmal disease or complete 
aortic occlusion extending up to the renal arteries. In 
addition, it is preferred by many vascular surgeons for 
routine use in most cases for several reasons. First, it 
appears to be more sound on a hemodynamic basis, 
with less turbulence, better flow characteristics, and 
less chance of competitive flow with still patent host 
iliac vessels. 24 Such considerations have led to better 
long-term patency and a lower incidence of late aor- 
tic anastomotic aneurysm in grafts constructed with 
end-to-end proximal anastomosis in some se- 
ries, 9'2s'26 although none has been a randomized 
prospective trial. Other studies, however, have not 
demonstrated any differences in late patency rates 
between the two types of  grafts. 27 30 Second, applica- 
tion of partially occluding tangential clamps for con- 
struction of an end-to-side anastomosis may carry a 
higher risk of dislodging intraaortic thrombus or 
atherosclerotic debris that may be difficult to com- 
pletely evacuate and be irretrievably carried to the 
pelvic circulation or lower extremities when clamps 
are released and flow restored. In addition, the infra- 
renal aorta will frequently be found to be quite calci- 
fied or difficult to work with to construct an end-to- 
side anastomosis despite the apparent appeal of this 
configuration suggested by preoperative arteriogra- 
phy. Finally, resection of a small segment of host 
aorta and the use of a short graft body or stem of the 
bifurcation graft for end-to-end anastomosis allow 
the prosthesis to be placed in the anatomic aortic 
bed, thereby facilitating subsequent tissue coverage, 
reperitonealization, a d separation of the graft from 
bowel. This may reduce the late occurrence of aor- 
toenteric fistula formation in subsequent years, al- 
though this has not been conclusively demonstrated 
by any series. 
End-to-side anastomosis appears to be poten- 
tially advantageous in certain anatomic patterns of 
disease.3 ~ For instance, if a large aberrant renal artery 
arises from the lower abdominal aorta or iliac arter- 
ies, or if the surgeon wishes to avoid sacrifice of a 
large patent inferior mesenteric artery (IMA), end- 
to-side proximal anastomosis allows preservation of 
such vessels and is an appropriate solution as long as 
the infrarenal aorta is relatively free of significant 
disease. Alternatively, they may be preserved by reim- 
plantation into the body of the graft if end-to-end 
insertion is preferred. It is worthwhile emphasizing 
that these are not frequent technical considerations. 
Significant accessory renal arteries arising from the 
lower aorta or iliac arteries are not commonly en- 
countered, and the IMA may be already occluded in 
a sizeable proportion of patients. Although advo- 
cated by some, a2 routine preservation ofa still patent 
IMA is unnecessary in my opinion; specific criteria 
and indications for maintaining IMA antegrade flow 
in a small percentage of aortic reconstructions have 
been previously elucidated. 33,34 
The most common pattern of disease potentially 
favoring end-to-side anastomosis  when the occlu- 
sive process is located principally in the external i iac 
vessels. In such instances division of the infrarenal 
aorta for end-to-end bypass to the femoral evel may 
et~kctivcly devascularize the pelvic region, because no 
retrograde flow up the external i iac arteries to supply 
the hypogastric arterial beds can be anticipated. This 
may potentially increase the incidence of erectile im- 
potence in the sexually potent male a5,36 or cause 
persistent and troublesome hip claudication symp- 
toms despite the presence of excellent distal pulses. 
Such hemodynamic consequences may also increase 
the incidence of clinically significant postoperative 
colon ischemia (1% to 2% in contemporary experi- 
ence), severe buttock ischemia, or even paraplegia 
caused by cauda cquina ischemia, although these 
later complications fortunately remain quite rare 
(<1%) in current practice. ~a,3'<a7,38 Finally, should a 
limb of such an end-to-end graft occlude in later 
years, the resulting limb ischemia may be particularly 
severe and lead to difficulty with healing of even 
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above-knee amputation, if further revascularization 
proves not to be feasible. 
Although preservation ofpelvic blood flow is the 
theoretic basis cited by those advocating end-to-side 
aortic anastomosis, it is interesting to note that sev- 
eral studies have questioned the validity of this con- 
cept. Mikati et al?9 studied agroup of 52 asymptom- 
atic patients by computed tomography scan 5 to 10 
years after end-to-side AFB was performed. They 
noted that 92% of patients had occluded native aor- 
toiliac segments that had been bypassed. 39Similar 
findings were reported by O'Connor et al., 4° who 
performed uplex scans on nine patients within a 
year of end-to-side ABF. Six of the nine patients had 
occluded distal aortas at a mean follow-up of 4 
months after surgery, yet all remained without symp- 
toms. 4° What is unknown, of course, is whether na- 
tive vessel flow persisted long enough for necessary 
collateral circulation to develop. For this reason an 
end-to-side reconstruction is often still advisable, if 
technically feasible, for the anatomic patterns of dis- 
ease described previously. 
Preferred site of  distal anastomosis. Although 
the distal anastomosis of the aortic graft may on 
occasion be accomplished atthe level of the external 
lilac arteries in the pelvis, it is almost always prefera- 
ble in patients with occlusive disease to carry the graft 
to the femoral level, where exposure is generally 
better and anastomosis easier from a technical stand- 
point. With adequate personnel both femoral anasto- 
moses may often be performed simultaneously. Most 
important, anastomosis atthe femoral level provides 
the surgeon an opportunity to ensure adequate out- 
flow into the profunda femoris artery. Experience has 
clearly demonstrated anincreased late failure rate of 
aortoexternal iliac grafts, with a higher incidence of 
subsequent "downstream" operations as a result of 
progressive disease at or just beyond the iliac anasto- 
mosis. 9'21'41 With meticulous surgical technique, 
proper skin preparation and draping, and use of a 
limited period of prophylactic antibiotic coverage, 
the feared higher incidence of infection if grafts were 
extended to the femoral level has not been borne out 
by extensive long-term experience. 9,H-14,42 How- 
ever, on occasion circumstances will clearly indicate 
the wisdom of avoiding incisions in the groin area, as 
for example in obese diabetic patients with an inter- 
triginous rash in the inguinal crease. 43 In this setting 
the risk of groin wound healing problems is signifi- 
cant, and iliac anastomosis may well be preferred if 
the external i iac vessels appear normal on angiogra- 
play and have no pullback pressure gradient with 
papaverine. 
Role of  profundaplasty. Establishment of ade- 
quate graft outflow at the level of the femoral anas- 
tomosis has been clearly documented to be of para- 
mount importance to both early and late graft 
patency and the hemodynamic results of revascular- 
ization in terms of symptom relief. 911,44-46 Coexis- 
tent outflow tract disease, most typically superficial 
femoral artery occlusion, will certainly limit hemody- 
namic improvement and hence the xtent of symp- 
tom relief resulting from an inflow procedure. 28The 
influence of infrainguinal disease on aortofemoral 
graft patency is less certain. Data from several series 
do not suggest any significant difference in late graft 
patency between patients with or without superficial 
femoral artery disease. 45,46 Other reports do sug- 
gest an adverse impact of outflow disease, with infe- 
rior (10% to 20% reduction) late patency of inflow 
grafts done in patients with distal occlusive dis- 
ease. 11,14,28;47 
Because 50% or more of patients undergoing 
aortofemoral grafts have multilevel disease, 31,48 the 
importance of establishing adequate profunda femo- 
ris flow is well recognized. 9,49~5a It is imperative in 
these circumstances that any profunda stenosis 
should be identified and corrected. Whether correc- 
tion of profunda origin disease is best achieved by a 
long beveled hood of the graft tip, by separate patch 
profundaplasty with prosthetic or autogenous tissue 
material, or indeed if formal profunda endarterec- 
tomy is also required, is less important than the basic 
31 43 48 52 principle of ensuring areliable outflow tract. • , • 
The importance of this tenet has raised the ques- 
tion of whether some form ofprofundaplasty should 
be done in all patients having aortofemoral grafts. 
Some authors have suggested that the mere existence 
of an occluded superficial femoral artery in itself 
causes a "functional" profunda stenosis approximat- 
ing a 50% diameter educing lesion, even in the 
absence of actual orificial disease of the profunda. 53 
However, the bulk of evidence suggests that "rou- 
tine" profundaplasty b whatever method in all such 
patients does not improve the hemodynamic result 
or late patency of the graft. 28 Therefore anastomosis 
to the common femoral artery is acceptable unless 
some actual proximal profunda disease is evident at 
the time of graft implantation. Although profunda 
disease may develop in later years in some patients, 
this may subsequently bedealt with more easily if the 
deep femoral artery has not been previously dissected 
and reconstructed already. This position does repre- 
sent some modification of my previous recommenda- 
tions in this regard 9 based principally on the careful 
analysis of Rutherford et al. 28 
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Management of  multilevel disease. A common 
dilemma in patients with multilevel disease is 
whether proximal revascularization alone will suffice. 
Although it is generally accepted that 75% to 80% of 
these patients will be improved by a properly per- 
formed aortic procedure, many series have docu- 
mented that from 25% to 33% of patients with mul- 
tilevel disease will fail to have sufficient relief of 
ischemic symptoms and may require later infraingui- 
nal procedures. 44-46,48 
I f  such patients could be identified before sur- 
gery, it would often be logical and beneficial to 
perform simultaneous inflow and outflow revascular- 
ization. Accurate prediction remains elusive, how- 
ever, and no single reliable indicator has been deter- 
mined. Nonetheless several criteria exist that 
together usually enable the surgeon to make this 
clinical judgment. 44,48,52 Factors to be considered 
include demonstration of only modest degrees of 
proximal inflow disease particularly in the presence of 
obviously extensivc and hemodynamically severe in- 
ftainguinal disease and a small or diffusely diseased 
profunda femoris not suitable for profundaplasty and 
likely to provide an inadequate collateral runoff tract 
to the lower extremity. Most important is the degree 
of distal ischemia. If the foot is severely ischemic as 
with ischemic necrosis or digital gangrene likely to 
require local amputation, it is clear that maximal 
revascularization is often mandated, if limb salvage is 
to be attained. 
In these circumstanccs synchronous proximal and 
distal reconstruction seems both desirable and ap- 
propriate, avoiding the difficulties and possible com- 
plications of later groin reopcrarion for staged by- 
pass and providing the best chance of relief of 
ischemic symptoms or salvage of the threatened 
limb. The frequcncy of combincd operation appears 
to be increasing significantly in contemporary prac- 
t i ces  ,54,55 The use of two surgical teams can consid- 
erably reduce additional operative time and thereby 
minimize the increased risk that was often cited in 
earlier years a an important reason to avoid simulta- 
neous proximal and distal bypass in favor of a staged 
approach. Indeed, several recent reports suggest no 
significant difference in perioperative mortality or 
major complications with synchronous inflow and 
outflow procedures compared with proximal recon- 
structions alone. 54,5s 
What is the best graft? Although standard fab- 
ric prosthetic grafts have generally performed well for 
aortofemoral reconstruction, i  recent years numer- 
ous modifications in graft material (Dacron vs poly- 
tetrafluoroethylene [PTFE], etc.), methods of fabri- 
cation (knitted vs woven, external vs double velour, 
porosity differences, etc.), and additions of various 
biologic coatings (collagen, gelatin, albumin) to the 
graft have been devised. Such alterations have been 
designed with the hope of improving the perfor- 
mance and characteristics of the graft: patency, dura- 
bility, healing, resistance to infection, reduced blood 
loss, and improved handling features. Various claims 
concerning the benefits of one type of graft over 
another have been made, but it is often difficult to 
discern science from salesmanship. 
In the early era of grafts many surgeons preferred 
knitted Dacron grafts for aortofemoral reconstruc- 
tion mainly because of their flexibility and ease of 
handling and suturing, which are particularly helpful 
when a difficult profunda anastomosis  necessary. 
However, no patency superiority of knitted versus 
woven grafts has been demonstrated. 56,57 In addi- 
tion, knitted grafts are more difficult to preclot and 
have been shown to undergo more dilatation over 
time than woven grafts. 58 Many currently manufac- 
tured woven prostheses of moderate porosity are less 
stiff than their low-porosity early versions and are 
easier to preclot han knitted grafts. Currently "zero 
porosity" coated grafts are quite popular mainly be- 
cause of their expediency and reduced blood loss. 
Their increased expense is often believed justified by 
saving of operative time, reduced transfusion eed, 
and perhaps lower morbidity as a result of lessened 
postoperative anemia, retroperitoneal hematoma, or 
both, all points with which I agree. PTFE bifurcation 
grafts are also a competitive choice. They are free of 
dilatation, have good healing properties, may be 
somewhat more resistant to infection, and are gener- 
ally easier to thrombectomize than fabric grafts, s9,6° 
The new "stretch" feature of some PTFE grafts com- 
pares favorably with crimped Dacron in its handling 
characteristics and ability to adjust o the appropriate 
length. 
One may currently conclude that no single large- 
caliber prosthesis i clearly superior for aortic recon- 
struction. Patency seems generally equivalent in the 
aortic position, so a choice should be based on other 
considerations such as andling properties, infectiv- 
ity, reduction of blood loss, and ease of reoperation 
(dissection, thrombectomy, or thrombolysis). Ob- 
jective scientific evaluation of these qualities is diffi- 
cult. Ultimately cost rather than such subjective and 
subtle attributes may determine the choice. 
Irrespective of the exact ype of graft material and 
fabrication, the use of the proper-sized graft is im- 
portant. Previously many surgeons used grafts that 
were too large in comparison with the size of outflow 
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tract vessels, which tended to promote sluggish flow 
in graft limbs and deposition of excessive laminar 
pseudointima in the prosthesis. This in turn may 
often have a propensity to later fragmentation or
dislodgement, leading to occlusion of one or both 
limbs of the graft. For occlusive disease a 16 x 8 mm 
bifurcated graft is most often used, with no hesita- 
tion to use a 14 × 7 mm or even smaller prosthesis 
when appropriate, as is frequently the case in some 
female patients with hypoplastic aortas. The limb size 
of such grafts will most closely approximate he fem- 
oral arteries of patients with occlusive disease or 
more particularly the size of the profunda femoris, 
which often remains as the only outflow tract. In 
addition, it is now well recognized that many Dacron 
prosthetic grafts have a tendency to dilate 10% to 
20% when subjected to arterial pressure. 5s Selection 
of a smaller graft size initially will help compensate 
for this problem. 
What is the best approach? In the past decade 
there has been a reawakening of enthusiasm for a 
retroperitoneal approach for aortic surgery. In addi- 
tion to some potential technical considerations, ad- 
vocates have claimed possible physiologic advantages 
such as less cardiac stress, reduced pulmonary distur- 
bance, decreased ileus, and lessened third-space fluid 
losses.61 63 
Most such data have related to aneurysm repair, 
however, and most of the suggested benefits have 
not been conclusively documented. Indeed, no sig- 
nificant outcome differences were found in our own 
randomized prospective study examining this i ssue .  64 
Although perhaps advantageous for certain complex 
aortic disease, routine use of a retroperitoneal p- 
proach for all cases of conventional aortofemoral 
grafting for standard aortoiliac occlusive disease can- 
not be recommended in my opinion. A major draw- 
back is that positioning often makes adequate xpo- 
sure of the right femoral artery and graft tunneling to 
the right groin difficult, particularly in the obese 
patient. Access to the right renal artery is poor, and if 
control and possible repair of the fight iliac artery 
may be necessary, this is often quite difficult with a 
left retroperitoneal approach. 
However, a retroperitoneal pproach may cer- 
tainly be advantageous in certain circumstances often 
related to technical i ssues .  64"66 Multiple previous in- 
traabdominal surgical procedures, previous aortic 
surgery, or other forms of "hostile" abdominal con- 
ditions are examples. I f significant juxtarenal or para- 
renal disease requires repair, or concomitant left re- 
nal artery revascularization r other visceral artery 
repair is necessary, a retroperitoneal approach may be 
quite helpful. For most cases of ABF for occlusive 
disease, however, I certainly prefer the standard mid- 
line transabdominal procedure. 
ABF VERSUS ALTERNATIVE 
PROCEDURES 
A paradox. Despite the well-documented dura- 
bility, effectiveness, and increasing safety of ABF, 
which have justifiably established it as the gold stan- 
dard of revascularization for aortoiliac occlusive dis- 
ease, it is paradoxic that one of the most successful 
procedures in vascular surgical practice is being used 
less and less frequently in current practice. Data from 
multiple sources clearly indicate that the percentage 
of patients with aortoiliac disease treated by direct 
aortic grafting is declining. 6771 Although a recently 
published report byStanley et al. 72 indicates that the 
total number of aortoiliofemoral bypass procedures 
performed over the last decade has remained rela- 
tively unchanged, it is likely that this reflects the 
growth of the aging patient population subject to 
occlusive disease and investigation and therapy of 
more patients with occlusive symptoms resulting 
from the availability of "less invasive" forms of treat- 
ment. Thus although the frequency or proportion of 
such patients treated by ABF is less, the total number 
of procedures may be maintained by virtue of more 
treated patients. 
Increasing use of alternative therapies, particu- 
larly catheter-based ndoluminal modalities uch as 
PTA, in place of ABF for treatment of symptomatic 
aortoiliac disease is attributable to several factors. 
Changing patient demographics and patient profiles 
are apparent to all practitioners; patients in current 
practice are indeed often older and sicker. Results of 
alternative methods have also improved as these 
techniques have undergone further evolution and 
refinement. In addition, the less invasive nature of 
these procedures has great patient appeal and is part 
of the considerable momentum towards minimally 
invasive care in all spheres of surgical practice within 
recent years. The potential advantages of alternative 
therapies are indeed attractive: reduced risk, reduced 
hospital stays, quicker recovery, and the perceived 
cost advantages stemming from these characteristics. 
Nonetheless itis important to recognize possible 
disadvantages of these methods as well. They are 
almost certainly less durable than ABF, often less 
effective in terms of incomplete revascularization, 
and generally less broadly applicable to patients with 
common (i.e., extensive) patterns of disease. All of 
these potential deficiencies may blunt possible cost 
benefits. In fact, the cost-effectiveness of many of 
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these methods compared with at of conventional 
treatment remains unproven. 
Iliac PTA and stents. Although some of the 
decrease in frequency with which ABF is performed 
is attributable to increased use of extraanatomic sur- 
gical bypass, it is clear that the major impact has been 
the marked increase in the use of iliac PTA and in 
recent years acceleration of this trend by the rapid 
growth of stents used in conjunction with balloon 
angioplasty. 
A remarkably arge variation in long-term success 
ofiliac PTA reported in the literature, exemplified by 
a range of 5-year cumulative patency rates from 32% 
to 92% noted in a review of a large number of reports 
comprising more than 6000 procedures, 73has clearly 
contributed substantially to confusion and contro- 
versy over the proper role for this method. Much of 
these differences relate to nonobjective methods of 
assessment, differing criteria of "success," short fol- 
low-up periods, and lack of consistent reporting stan- 
dards. 74 Many investigators have eliminated initial 
PTA failures in assessing late results, and "patency" 
may not be the ultimate consideration, because most 
lesions selected for PTA were stenotic lesions and 
therefore patent o begin with. 
Two carefully performed studies by Johnston et 
al. 75,76 have done much to objectively assess results of 
iliac PTA and indicate when this may be considered a 
reasonable alternative to conventional surgical repair. 
Results of their prospective study of 667 iliac PTA 
procedures demonstrated that chances of long-term 
success can be accurately predicted depending on 
four key variables: indication, site, severity, and run- 
off. In the most favorable circumstance, that of a 
localized common iliac stenosis in a patient with 
claudication alone and good runoff, a 3-year success 
rate of 68% was noted (Table I). Conversely, for 
common or external i iac occlusion in patients with 
limb-threatening ischemia and poor runoff, a suc- 
cessful result was noted in only 10% to 20% of pa- 
tients. Overall, the 3-year success rate of iliac PTA 
determined in the Toronto experience was approxi- 
mately 60%, certainly considerably inferior to that 
routinely achieved in all surgical series. 76 
A true comparison of iliac PTA with ABF is diffi- 
cult, because the anatomy (distribution and extent) 
and severity of disease are usually quite different in 
patients elected for each method of treatment. Few 
randomized prospective data exist. In one study by 
Wilson et al.77 comparing patients with limited dis- 
ease suitable for treatment by either modality, the 
overall cumulative long-term success rate favored 
surgery (81% vs 62% success rate at 3 years). This 
Table I. Three-year results ofpercutaneous 
transluminal ngioplasty performed at the 
University of Toronto 
3-Year 
Severity of Other success rate 
stenosis Site of PTA variables (%) 
Occlusion Iliac 1 si*:e 66* 
>1 site 17" 
Stenosis Common iliac 68 t 
External iliac Male 57* 
Female 34* 
Both common Good runoff 73* 
and external Poor runoff 30* 
iliac 
*Cox regression analysis. 
tlLaplan-Meicr analysis. 
From Johnston ICvV. Iliac arteries: reanalysis of results of balloon 
angioplasty. Radiology 1993;186:207-12. 
statistically significant difference between surgery and 
PTA was due almost entirely to the initial failure rate 
of PTA (15.5%) rather than to late PTA' failures. In 
fact, if early PTA failures are excluded, the durability 
of the two methods appears equivalent. In a similar 
randomized prospective trial from Holm et al.78 in 
Sweden, immediate and 1-year results of PTA and 
surgery were equivalent, and patients who under- 
went PTA had a significantly shorter hospital stay. It 
is important to note, however, that only patients who 
could be treated by both methods were included, 
constituting only 5% of the total number of patients 
treated uring the study period. 
It appears reasonable to conclude at present that 
iliac PTA does have an established and valuable role 
in the treatment of selected patients with aortoiliac 
disease and should be considered as potential pri- 
mary therapy, if the chances of long-term success are 
good. Proper criteria for its use have been fairly well 
established and consist principally of localized dis- 
ease, ideally short stenotic lesions in the common 
iliac arteries. 7s,76,79 Iliac PTA for focal iliac disease is 
also a valuable adjunct when combined with distal 
surgical procedures in appropriate patients with mul- 
tilevel occlusive disease, s°-s2 Given these indications, 
iliac PTA may be a reasonable alternative to ABF or 
related surgical procedures in perhaps 10% to 15% of 
patients with aortoiliac diseasc. Or PTA may have a 
potential role to extend indications for intervention 
in patients with milder symptoms who would not 
normally be considered for surgical therapy. Al- 
though long-term clinical success even in these favor- 
able subsets of patients appears to be less than with 
surgical reconstruction, the likely benefits in terms of 
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Table II. Comparison of results obtained 
with PTA and stenting (Palmaz series) and 
PTA alone (Toronto series) 
Parameter PTA Only PTA and 
evaluated (Toronto Series) 7° Stent 8z 
No. of  centers 1 center Multicenter 
No. of cases 587 procedures 662 procedures 
Criteria for success Clinical and objective Clinical 
vascular laboratory 
measurements 
Initial success rate 93% I00% 
3-yr success rate 60% 69% 
From Johnston KW. Balloon angioplasty and stents: their place in 
treating iliac, femoral, and popliteal occlusive disease. American 
College of Surgeons Postgraduate course in Vascular Surgery, 
New Orleans, LA, October 1995. 
decreased morbidity and probable cost savings may 
well justify its use in these circumstances. 
Whether stents can improve late results of iliac 
PTA and thereby extend indications for its use to 
include more aggressive catheter-based treatment of 
a greater proportion of patients with more extensive 
aortoiliac disease (longer diseased segments, multiple 
lesions, total occlusions) remains much more unset- 
tled and is thus the topic of considerable current 
debate and controversy. Selective use of stents may 
well improve early results of PTA in some cases, if 
inadequate hemodynamic mprovement is attribut- 
able to technical factors leading to insufficient recan- 
alization such as "elastic recoil" of dilated segments 
or localized dissections of dilated plaques, which 
produce flow obstruction. 73,83 However, if a poor 
hemodynamic result reflects diffuse disease or multi- 
ple "subcritical" serial esions, the benefit ofstenting 
is less well established. The use of stents may also 
improve late results of PTA for total iliac occlu- 
sions, 84,a5 but late patency of recanalized total iliac 
occlusions even with stents is clearly below that 
achieved by surgical bypass methods. Other criteria 
to justify the use of stents on a routine basis to 
improve long-term results of iliac PTA remain un- 
clear. It is difficult o understand how stents can be 
anticipated to reduce or retard development of inti- 
mal hyperplasia or progressive atherosclerosis, which 
are the other major mechanisms oflate PTA failure. 86 
As shown in Table II the multicenter t ial of Palmaz 
et al. 87 with the Palmaz stent showed a3-year success 
rate 9% higher (69% vs 60%) than that of the Toronto 
experience with PTA alone. 7s,76 However, analysis of 
these reports reveals that this difference is largely 
attributable to a 7% higher initial success rate, which 
appears to be due to exclusion of technical and early 
failures in the Palmaz series. Thus on an intention- 
to-treat basis the use of stents provided little if any 
late benefit. 86 
Richter et al. 88,89 have reported preliminary re- 
sults in several abstracts of a widely cited prospective 
randomized study comparing balloon angioplasty 
and stenting for iliac artery disease; however, a de- 
tailed publication is still not available nearly 4 years 
later despite widespread claims of superior results 
with stents. The interim data do suggest a clear 
advantage for the routine use ofstents, with a 92.7% 
5-year clinical success rate for iliac stenting compared 
with 69.7% for PTA alone. However, final conclu- 
sions as to the validity of the study and general 
application of its findings must await detailed publi- 
cation. 86 This example serves to emphasize the need 
for properly reported etailed analysis of long-term 
results, which is imperative for informed decision 
making. 
At present, caution concerning overzealous appli- 
cation of stenting and broadening of indications for 
iliac PTA seems warranted. 9°Although effective for 
localized disease, most patients with symptomatic 
aortoiliac disease severe nough to merit revascular- 
ization have more diffuse patterns of disease that are 
generally best corrected from a long-term perspec- 
tive by surgical bypass procedures. While appealing 
for its expediency and potentially lower morbidity, 
the inferior durability of PTA and possible need for 
multiple reinterventions must also be considered. 
Potential cost advantages ofminimally invasive treat- 
ments in general will be diminished if frequent rein- 
terventions are required, as has been amply demon- 
strated with coronary angioplasty. 91 Cost-benefit 
analysis must therefore recognize the additional ex- 
pense of repeat procedures and not simply initial 
therapy. . ,  aconcept of "lifetime treatment cost." It 
is also clear that increased use of stenting to treat 
more extensive disease requires deployment of mul- 
tiple stents. At $600 to $1000 per stent it is obvious 
that insertion of four or five stents in a single patient 
will largely offset any procedural cost advantages. In
addition, although failure of PTA is generally be- 
lieved to seldom preclude or complicate later surgical 
revascularization, deployment of multiple stents 
throughout the aortoiliac system may indeed make 
subsequent operation more difficult or hazardous. 
Finally, it seems certain that the expanded use of 
endoluminal modalities to treat more extensive and 
complex disease will undoubtedly require increased 
procedure time, a need for additional medical and 
ancillary personnel, and more sophisticated equip- 
ment, all factors that diminish cost advantages ofless 
invasive therapies. 92A good example of this phe- 
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nomenon, of course, is the finding of equivalent or 
even higher costs of thrombolytic therapy compared 
with surgery for the treatment of artery or graft 
th rombos is .  93,94 Thus the potential cost advantages 
of treating iliac occlusions by initial thrombolysis n 
the hopes ofunmasldng a stenotic lesion suitable for 
PTA and stent insertion may not be as significant as 
first anticipated. 
Extraanatomic grafts. Since their introduction 
in the early 1960s for management of difficult and 
often desperate t chnical problems usually related to 
infection or failure of previous grafts, 9s,96 the use of a 
variety of extraanatomic bypasses has increased to 
include wider application in patients perceived to be 
at high risk for conventional ABF or for those with 
more limited disease not otherwise suitable for PTA 
or stents. 97q°4 In these circumstances the goal is to 
achieve revascularization bymeans of grafts that use 
remote, frequently subcutaneous pathways and po- 
tentially can be performed with lower morbidity and 
mortality. 
Whether such reconstructive options represent 
reasonable alternatives toABF in a greater number of 
patients remains ill defined at present. Currently 
most debate centers on two areas: the most appropri- 
ate management of unilateral iliac disease and the 
possible expanded role of axillofemorai (Ax-Fem) 
grafts suggested by recently reported improved re- 
suits. 105-10s 
As is the case with consideration of the role of 
PTA, a considerable part of uncertainty regarding 
these issues is related to substantial variations in re- 
ported long-term effectiveness ofthese surgical alter- 
natives) °9 For example, a review of the literature 
reveals 3- to 5-year patencies of Ax-Fem grafts rang- 
ing from 10% to 85%. ~°°-~°2,n°q2~ Thisis due in part 
to inconsistencies of reporting methods in some ear- 
lier series, which reported secondary rather than pri- 
mary patency rates, and to the confounding influence 
of combining results of grafts used in differing clini- 
cal settings. As emphasized by Rutherford et al.,109 
the results of extraanatomic grafts are quite different 
in patients with good versus poor runoff (superficial 
femoral artery status) or when used as primary proce- 
dures versus reoperative reconstruction for failure of 
previous grafts. 1°9 Thus a more detailed consider- 
ation of specific clinical indications and anatomic 
patterns of disease is necessary to more accurately 
predict likely outcome and attain a perspective on the 
application of such methods. 
Although aortoiliac disease is generally a diffuse 
process eventually involving both iliofemoral arterial 
segments, it is not uncommon that patients will man- 
ifest largely unilateral symptoms with a normal fem- 
oral pulse and absence of ischemic symptoms in the 
contralateral limb. In this setting the question fre- 
quently arises as to whether a conventional aorto- 
bifemoral graft or a more limited reconstruction 
aimed at treatment of only the symptomatic side 
should be done. Femorofemoral (FF) and iliofemoral 
(IF) bypasses are the most commonly used surgical 
alternatives toABF in these circumstances. Although 
endarterectomy ay also be performed for relatively 
localized unilateral i iofemoral disease, 1°7,122,123 this 
has been largely supplanted in the current era by PTA 
and stenting. 
Both FF and IF bypass can provide highly satis- 
factory long-term patency and relief of ischemic 
symptoms in properly selected patients, particularly 
when adjunctive profundaplasty is also carried out 
when indicated. 1°7,n3,124-13° IF grafts may have 
somewhat better late patency rates and also the addi- 
tional advantage of avoiding surgery and possible 
complications on the opposite asymptomatic 
limb. 1°6,129-132 On the other hand, FF bypass is gen- 
erally easier, involves less dissection, and therefore 
has a lower morbidity risk. FF grafts can also be used 
for patients with common iliac artery occlusion or 
hea W calcification, which preclude IF bypass, and 
carry the least risk of postoperative disturbance of 
sexual function, which may be a consideration i  
young low-risk patients. 
Nonetheless the patency rate of either alternative 
is less than that of ABF, and the hemodynamic per- 
formance of extraanatomic grafts uch as FF bypass is 
often inferior) 33 Furthermore the use of unilateral 
reconstructions may lead to the later need for opera- 
tion on the contralateral side because of progressive 
disease in the aorta or opposite iliac artery. Although 
the frequency of this event is quite variable in the 
literature, ranging from 5% to 38% of patients in 
differing series, 21,1°s,1°6,128,132,134,135 it is aconsider- 
ation perhaps favoring ABF in a young patient at low 
risk. ABF grafts also do not appear to be as adversely 
influenced by the presence of runoff disease or limb 
salvage indications for operation as do extraanatomic 
reconst ruct ions .  1°53°9'126-129'131"132 Thus for older 
patients with significant comorbid conditions, use of 
FF or IF bypass to treat unilateral iliac disease is often 
a practical choice. In young patients at low risk ABF 
is still preferred in most instances in my view. 
Even more controversial is the recent claim that 
contemporary esults of Ax-Fem bypasses have im- 
proved dramatically and are now essentially equiva- 
lent to those achieved by conventional ABF grafts, l°s 
Since the introduction of axillo-unifemoral 9s,136 and 
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axillo-bifemoral grafts la7 in the 1960s, all vascular 
surgeons have recognized the utility of such ex- 
traanatomic alternatives for specific indications, usu- 
ally involving infection, obviously hostile intraab- 
dominal disease, or truly prohibitive risk patients. 
However, it was generally agreed that Ax-Fem grafts 
represented a compromise selection, trading inferior 
long-term durability and less comprehensive h mo- 
dynamic improvement for a lower morbidity and 
mortalit T risk.9S,~0~ ,109-111,115,116,118 
This view has been challenged by the recent re- 
port of Passman et al. l°s from Portland. These au- 
thors described results of a prospective concurrent 
comparison of 117 Ax-Fem and 139 ABF grafts 
during the 6-year period of 1988 through 1993. 
Patients were not randomized, however, and proce- 
dure choice was made by each surgeon based on 
assessment of surgical risk. Patients undergoing Ax- 
Fem grafts were older, had more comorbid condi- 
tions, and were operated on for limb salvage indica- 
tions more often. Mthough 5-year primary patency 
(80% ABF, 75% Ax-Fem) and operative mortality 
(<1% ABF, 3.4% Ax-Fem) results favored the con- 
ventional ABF procedure, these differences were not 
statistically significant. Major postoperative compli- 
cations were noted to be more frequent after ABF 
(ABF 20.9%, Ax-Fem I0.3%, p < 0.05%). No signif- 
icant difference in 5-year limb salvage rates were 
detected. Not unexpectedly, 5-year patient survival 
was significantly inferior for Ax-Fem bypass (45% 
Ax-Fem, 72% ABF). These results prompted the Or- 
egon group to question the prevailing opinion that 
ABF constitutes the "gold standard" for inflow re- 
vascularization. 
Passman et al3 °s stress that the modern day re- 
sults of ABF in the patient population currently re- 
quiring surgical revascularization for aortoiliac dis- 
ease are largely unlmown. They emphasize that many 
older series that are frequently used for reference 
standards included a high percentage of patients op- 
erated on for claudication alone and with relatively 
localized isease, more favorable circumstances often 
treated today by other modalities uch as PTA, etc. 
Furthermore they note other recently reported series 
that also describe similar improved results of Ax-Fem 
bypass.~ 9,z20,13s-140 
This experience certainly merits careful review 
and evaluation if the Oregon group's omewhat pro- 
vocative conclusions are to be accepted. Most of the 
data reflecting better patency rates of Ax-Fem grafts, 
with S-year primary patency rates exceeding 70%, 
have come from the multiple reports of the Seat- 
tie 119,1s8 and Portland 1°s,12°,139 groups and have co- 
incided with the introduction of externally supported 
grafts by Sauvage t al.141 Most speculation concern- 
ing the possible xplanation from improved durabil- 
ity of Ax-Fem grafts has centered on the possible 
benefit of external support in preventing compres- 
sion and occlusion of these grafts in their subcutane- 
ous position. The possible adverse role of compres- 
sion particularly during sleep at nighttime and the 
vulnerability of Ax-Fem grafts to such compression 
or kinking have long been recognized, 1n,121 al- 
though two studies examining this issue have 
reached conflicting conclusions. 142,14s Although tl~e 
benefit of externally supported conduits has not been 
conclusively demonstrated, it seems reasonable to 
assume that it may indeed be helpful for grafts in the 
Ax-Fem position. Graft material itself does not ap- 
pear to be a significant influence, because Sauvage's 
group has achieved similar results with externally 
supported Dacron prostheses, n9 Other studies have 
also noted no clear difference in patency rates be- 
tween PTFE and Dacron grafts for Ax-Fem recon- 
struction, 121'144 although one report has described 
superior esults with PTFE grafts.~4s Irrespective of 
graft material Ax-Fem grafts are more prone to infec- 
tion than ABF, a factor that must also be recognized 
in any comparison of late outcomeJ 46 
Improved results with Ax-Fem grafts might also 
be attributable to evolution and refinement of tech- 
nical aspects of the procedure. It is obviously impor- 
tant to screen for possible impaired subclavian or 
axillary inflow on the donor side347 The Oregon 
group has stressed a two-team approach, medial 
placement of the proximal anastomosis on the axil- 
lary artery, a redundant curve of the graft proximally 
nearly parallel to the adjacent axillary artery, and 
insertion of the femorofemoral graft first with subse- 
quent distal Ax-Fem anastomosis to the hood of the 
FF bypass, l°8,ls9J48 However, data to support any 
advantage of various uggested anastomotic configu- 
rations do not exist, and any claims concerning al- 
leged benefits remain unconfirmedJ °9,149-1sl 
Previous studies comparing concurrent Ax-Fem 
and ABF results are retrospective, but all showed 
superior patency results of the traditional anatomic 
reconstruction. 1°2A13,l18,ls2 Johnson et al)00 
claimed equivalent outcome but used secondary Ax- 
Fern patencies for their comparison. The report of 
Passman et a1308 is prospective but not randomized. 
There are no prospective randomized trials to pro- 
vide definitive data. Neither are there data to suggest 
that current results of ABF in today's patient popula- 
tion are necessarily inferior to those previously pub- 
lished, one of the Oregon group's principal assump- 
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tions. Finally, their viewpoint must be validated by 
other studies. Indeed, other recent reports, as for 
example by Harrington et al., l i t  do no show any 
benefit of externally supported grafts or better esults 
in grafts performed in the more recent time era. 
At present, I would agree that Ax-Fem grafts 
should be regarded as acceptable alternatives for in- 
flow operation with specific advantages and disad- 
vantages and may be more liberally applied in current 
practice for appropriate clinical indications without 
undue concern about poor long-term results. How- 
ever, they are not equivalent in durability or effi- 
ciency to AFB grafts and remain a second choice in 
my opinion. 
Current perspective. It is clear that no single 
option for inflow revascularization is optimal in all 
instances. In every pauent a decision about which 
method is the best choice is made by consideration f
several factors. These include primarily the extent 
and distribution of disease and the anticipated risk of 
the possible alternatives that might be used. The 
likely success of various methods in terms of hemo- 
dynamic improvement, symptom relief, and sus- 
tained patency can usually be predicted with relative 
accuracy, and such estimates must be judged in the 
context of patient age, expected length of survival, 
and specific linical needs of each patient. Durability 
must often be balanced against he possible advan- 
tages of safety and expediency. 
Alternative therapies have a well-established role 
in the management of occlusive disease of limited 
extent or lesser severity and in the treatment of pa- 
tients with adverse technical challenges or high oper- 
ative risk for conventional direct aortic reconstruc- 
tion. However, for most patients with diffuse 
aortoiliac occlusive disease, ABF grafts remain the 
most durable and functionally effective means of re- 
vascularization and should continue to be rightfully 
regarded as the gold standard or basis of comparison 
with which other options must be properly com- 
pared. It is worth remembering that as the availability 
and results of alternative techniques have improved, 
so too has the safety of standard repair. Indeed, the 
very definition of a "high-risk" patient is currently 
much more indistinct than in previous eras. No 
doubt the future will bring new advances in alterna- 
tive methods, but it is hoped that properly designed 
and performed randomized studies, outcome assess- 
ment, and cost-benefit analyses will help clarify their 
role. The need for such data is quite evident; without 
it, one of the most effective and beneficial procedures 
that vascular surgeons have to offer may be inappro- 
priately abandoned because of the seductive guise of 
"less is best." 
In the final analysis the alternatives for inflow 
revascularization may not be as competitive with one 
another as first seems apparent. Each has its own 
specific advantages and disadvantages and when used 
in appropriate circumstances can give excellent re- 
sults. Indeed, it is this very broad spectrum of op- 
tions that makes treatment of aortoiliac occlusive 
disease one of the most succcssful areas of current 
vascular practice. 
REFERENCES 
1. DeBakey ME, Lawrie GM, Glaeser DH. Patterns of athero- 
sclerosis and their surgical significance. Ann Surg 19 8 5;2 01: 
115-31. 
2. Brewster DC. Clinical and anatomic onsiderations for sur- 
gery in aortoiliac disease and results of surgical treatment. 
Circulation 1991;83(Suppl I):I-42-52. 
3. Dos Santos ~C. Sur la desobstruction des thromboses arteri- 
elles anciennes. Mere Acad Chit 1947;73:409-11. 
4. Wylie EJ, Kerr E, Davies O. Experimental nd clinical expe- 
riences with the use of fascia lata applied as a graft about 
major arteries after thrombo-endarterectomy and aneu- 
rysmsmorrhaphy. Surg Gynecol Obstet 1951;93:257-72. 
5. Oudot 1. La greffe vasculaire dans les thromboses du carte- 
four aortique. Presse Med 1951;59:234-8. 
6. Voorhees AB Jr, Jaretzld A III, Blakemore AH. Use of tubes 
constructed from Vinyon "N" cloth in bridging arterial 
defects: preliminary report. Ann Surg 1952;135:332-6. 
7. Edwards SW, Lyons C. Three years' experience with periph- 
eral arterial grafts of crimped nylon and teflon. Surg Gynecol 
Obstet 1958;107:62-8. 
8. DeBakey ME, Cooley DA. Clinical application of a new 
flexible imitted Dacron arterial substitute. Am Surg 1958; 
24:862-9. 
9. Brewster DC, Darling RC. Optimal methods of aortoiliac 
reconstruction. Surgery 1978;84:739-48. 
10. Brewster DC, Cooke ~C. Longevity of aortofemoral bypass 
grafts. In: Yao JST, Pearce WH, editors. Long-term results 
in vascular surgery. East Norwalk: Appleton and Lange, 
1993:149-61. 
11. Malone JM, Moore WS, Goldstone J. The natural history of 
bilateral aorto-femorai bypass grafts for ischemia of the lowe 
extremities. Arch Surg 1975;110:1300-6. 
12. Crawford ES, Bomberger RA, Glaeser DH, Saleh SA, Rus- 
sell WL. Aortoiliac occlusive disease: factors influencing sur- 
vival and function following reconstructive operation over a 
twenty~flve year period. Surgery 1981;90:1055-67. 
13. Szilagyi DE, Elliott ~P Jr, Smith RF, Reddy DJ, McPharlin 
M. A thirty-year survey of the reconstructive surgical treat- 
merit of aortoiliac occlusive disease. J Vasc Surg 1986;3: 
421 36. 
14. Nevelsteen A, Wouters L, Suy R. Aorto-femoral Dacron 
reconstruction for aortoiliac occlusive disease: a 25 year 
survey. Eur l Vasc Surg 1991;5:179-86. 
15. Poulias GE, Doundoulalds N, Prombonas E, Haddad M, 
Papaioannou K, Lymberiades D, et al. Aorto-femoral bypass 
and determinants of early success and late favorable out- 
come: experience with 1000 consecutive cases. ~ Cardiovasc 
Surg 1992;33:664-78. 
JOURNAL OF VASCULAR SURGERY 
376 Brewster February 1997 
16. Wylie EJ. Thromboendarterectomy for arteriosclerotic 
thrombosis of major arteries. Surgery 1952;32:275-90. 
17. Barker WF, Cannon JA. An evaluation of endarterectomy. 
Arch Surg 1953;66:488-95. 
18. Darling RC, Linton RK Aortoiliofemoral endarterectomy 
for atherosclerotic o clusive disease. Surgery 1964;55:184- 
94. 
19. Inahara T. Evaluation of endarterectomy for aortoiliac and 
aortoiliofemoral occlusive disease. Arch Surg 1975;110: 
1458-64. 
20. van den Akker PJ, van Schilfgaarde i% Brand R, Van Bockel 
JH, Terpstra JL. Long-term results of prosthetic and non- 
prosthetic reconstruction for obstructive aorto-iliac disease. 
Eur J Vasc Surg 1992;6:53-61. 
21. Crawford ES, Manning LG, Kelly TF. "Redo" surgery after 
operations for aneurysm and occlusion of the abdominal 
aorta. Surgery 1977;81:41-52. 
22. Perdue GD, Long WD, Smith RB III. Perspective concern- 
ing aortofemoral rterial reconstruction. Ann Surg 1971; 
173:940-4. 
23. Ehrenfeld WK, Wilber BC, Olcott CN, Stoney RJ. Autoge- 
nous tissue reconstructiom in the management of infected 
prosthetic grafts. Surgery 1979;85:82-92. 
24. JuleffRS, Brown OW, McKain MM, Clover JL, Bendick PJ. 
The influence of competitive flow on graft patency. J Car- 
diovasc Surg 1992;33:415-9. 
25. Mulcare RJ, Royster TS, Lynn RA, Connors RB. Long-term 
results of operative therapy for aortoiliac occlusive disease. 
Arch Surg 1978;113:601-4. 
26. Pierce GE, Turrentine M, Stringfield S, Iliopoulos J, Hardin 
CA, Hermreck AS, et al. Evaluation of end-to-side v end-to- 
end proximal anastomosis in aortobifemoral bypass. Arch 
Surg 1982;117:1580-8. 
27. Dunn DA, Downs AlL, Lye CtC Aortoiliac reconstruction 
for occlusive disease: Comparison of end-to-end and end-to- 
side proximal anastomoses. Can J Surg 1982;25:382-4. 
28. Rutherford RB, Jones DN, Martin MS, Kempczinski RF, 
Gordon RD. Serial hemodynamic assessment of aortob- 
ifemoral bypass. J Vasc Surg 1986;4:428-35. 
29. Ameli FM, Stein M, Aro L, Provan JL, Gray R, Grossman H. 
End-to-end versus end-to-side proximal anastomosis n aor- 
tobifemoral bypass surgery: does it matter? Can J Surg 1991; 
34:243-6. 
30. Melliere D, Labastie J, Becquemin J-p, ICassab M, Paris E. 
Proximal anastomosis n aorto-bifemoral bypass: end-to-end 
or end-to-side? J Cardiovasc Surg 1990;31:77-80. 
31. Brewster DC. Direct reconstruction for aortoiliac occlusive 
disease. In: Rutherford RB, editor. Vascular surgery. 4th ed. 
Philadelphia: WB Saunders, 1995:766-94. 
32. Seegar JM, Coe DA, ICaelin LD, Hynn TC. Routine reim- 
plantation of patent inferior mesenteric arteries limits colon 
infarction after aortic reconstructions. J Vasc Surg 1992;15: 
635-41. 
33. Ernst CB. Prevention of intestinal ischemia following ab- 
dominal aortic reconstruction. Surgery 1983 ;93:102 -6. 
34. Brewster DC, Frauldin DP, Cambria RP, Darling RC, Man- 
cure AC, LaMuraglia CM, et al. Intestinal ischemia compli- 
cating abdominal ortic surgery. Surgery 1991;109:447-54. 
35. Flanigan DP, Schuler JJ, Keller T, Schwartz JA, Lira LT. 
Elimination of iatrogenic impotence and improvement of 
sexual function after aortoiliac revascniarization. Arch Surg 
1982;117:544-50. 
36. Querai LA, Whitehouse WM Jr, Flilm WR, Zarins CK, 
Bergan JJ, Yao JST. Pelvic hemodynamics after aortoiliac 
reconstruction. Surgery 1979;86:799-809. 
37. Picone AL, Green RM, Ricotta JR, May AG, DeWeese JA. 
Spinal cord ischemia following operations on the abdominal 
aorta. J Vasc Surg 1986;3:94-103. 
38. Gloviczki P, Cross SA, Stanson AW, Carmichael SW,Bower 
TC; Pairolero P, et al. Ischemic injury to the spinal cord or 
lumbosacral plexus after aorto-iliac reconstruction. Am J 
Surg 1991;162:131-6. 
39. Mikati A, Marache P, Watel A, Warembourg H, Roux JP, 
Nobler D, et al. End-to-side aortoprosthetic anastomoses: 
long-term computed tomography assessment. Ann Vase 
Surg 1990;4:584-91. 
40. O'Connor SE, Walsh DB, Zwolak RM, Schneider JR, 
Cronenwett JL Pelvic blood flow following aorto-bifemoral 
bypass with proximal end-to-end anastomosis. Ann Vase 
Surg 1992;6:493-8. 
41. Baird RJ, Feldman P, Miles JT, et ai. Subsequent down- 
stream repair after aorta-lilac and aorta-femoral bypass oper- 
ations. Surgery 1977;82:785-93. 
42. Moore WS, Cafferata HT, Hall AD, et al. In defense of grafts 
across the inguinal igament: an evaluation f early and late 
results of aorto-femoral bypass grafts. Ann Surg 1968;168: 
207-14. 
43. Rutherford RB. Aortobifemoral bypass, the gold standard: 
technical considerations. Semin Vasc Surg 1994;7:11-6. 
44. Brewster DC, Perler BA, Robison JG, et al. Aortofcmoral 
graft for multi-level occlusive disease: predictors of success 
and need for distal bypass. Arch Surg 1982;117:1593-600. 
45. Martinez BD, Hertzer NR, Beven EG. Influence of distal 
arterial occlusive disease on prognosis following aortob- 
ifemoral bypass. Surgery 1980;88:795-805. 
46. Hill DA, McGrath MA, Lord RSA, et al. The effect of 
superficial femoral artery occlusion on the outcome of aort- 
ofemoral bypass for intermittent daudication. Surgery 1980; 
87:133-6. 
47. Harris PL, Cave Bigley DJ, McSweeney L. Aortofemoral 
bypass and the role of concomitant femorodistal reconstruc- 
tion. Br J Surg 1985;72:317-20. 
48. Brewster DC, Veith FJ. Combined aortoiliac and femoropo- 
pliteal occlusive disease. In: Veith FJ, Hobson RW, Williams 
RA, Wilson SE, editors. Vascular surgery: principles and
practice. 2nd ed. New Yorlc McGraw-Hill, Inc, 1994:459- 
72. 
49. Bernhard VM, Ray LI, Militello JP. The role of angioplasty 
in the profunda femoris artery in revascularization of the 
ischemic limb. Surg Gynecol Obstet 1976;142:840-4. 
50. Malone JM, Goldstone J, Moore WS. Autogenous pro- 
fundaplasty: the key to long-term success and need for distal 
bypass. Arch Surg 1982;117:1593-600. 
51. Morris GC Jr, Edwards W, Cooley DA, et al: Surgical impor- 
tance of the profunda femoris artery: analysis of 102 cases 
with combined aortoiliac and femoropopliteal occlusive dis- 
ease treated by revascularizafion of the deep femoral artery. 
Arch Surg 1961;82:32-7. 
52. Brewster DC, Meier GH III, Darling PC, et al. Reoperation 
for aortofemoral graft limb occlusion. Optimal methods and 
long-term results. J Vasc Surg 1987;5:363-74. 
53. Berguer R, Higgins RF, Cotton LT. Geometry, blood flow, 
and reconstruction of the deep femoral artery. Am J Surg 
1975;130:68-73. 
54. Nypaver TJ, Ellenby MI, Mendoza O, et al. A comparison of 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 2 Brewster 377 
operative approaches and parameters ofsuccess in multilevel 
arterial occlusive disease. J Am Coil Surg 1994;179:449-56. 
55. Dalman RL, Taylor LM Jr, Moneta GL, etal. Simultaneous 
operative repair of multilevel lower extremity occlusive dis- 
ease. J Vasc Surg 1991;13:211-21. 
56. Robicsek F, Duncan GD, Daugherty HK, et al. "Half and 
half" woven and knitted Dacron grafts in the aortoiliac and 
aortofemoral positions: seven and one-half years follow-up. 
Ann Vasc Surg 1991;5:315-9. 
57. Robicsek F, Duncan GD, Anderson CE, etai. Indium III- 
labeled platelet deposition in woven and knitted Dacron 
bifurcated aortic grafts with the same patient as a clinical 
model. J Vasc Surg 1987;5:833-7. 
58. Nunn NB, Carter MM, Donahue MT, et al. Postoperative 
dilation of knitted Dacron aortic bifurcation graft. J Vasc 
Surg 1990;12:291-7. 
59. Cintora I, Pearce DE, Cannon JA. A clinical survey ofaorto- 
bifemoral bypass using two inherently different graft types. 
Ann Surg 1988;208:625-30. 
60. Friedman SG, Lazzaro RS, Spier L, etal. A prospective 
randomized comparison of Dacron and polytetrafluoroeth- 
ylene aortic bifurcation grafts. Surgery 1995;117:7d0. 
61. Sicard GA, Freeman MB, VanderWoude JC, Anderson CB. 
Comparison between the transabdominal nd retroperito- 
neal approach for reconstruction fthe infrarenal abdominal 
aorta. J Vasc Surg 1987;5:19-27. 
62. Sicard GA, Reilly JM, Rubin BG, et al. Transabdominal 
versus retroperitoneal incision for abdominal aortic surgery: 
report of a prospective randomized trial. J Vasc Surg 1995; 
21:174-83. 
63. Leather RP, Shah DM, ICaufman JL, et al. Comparative 
analysis of retro-peritoneal nd transperitoneal ortic re- 
placement for aneurysm. Surg Gynecol Obstet 1989;168: 
387-93. 
64. Cambria RP, Brewster DC, Abbott WM, etal. Transperito- 
nea! versus retro~peritoneal approach for aortic reconstruc- 
tion: a randomized prospective study. J Vasc Surg 1990;11: 
314-25. 
65. Shepard AD, Tollefson DFJ, Reddy DJ, etal. Left flank 
retroperitoneal exposure: a technical aid to complex aortic 
reconstruction. J Vasc Surg 1991;14:283-91. 
66. Williams GM, Ricotta J, Zinncr M, Burdick 1. The extended 
retroperitoneai approach for treatment of extensive athero- 
sclerosis of the aorta and renal vessels. Surgery 1980;88:846- 
55. 
67. Bernstein EF, Dilley RB, Thomas WS, et al. Changing prac- 
tice patterns in peripheral arterial disease. Ann Vasc Surg 
1994;8:186-94. 
68. Ernst CB. The indications for iliac angioplasty or whatever 
happened to aortofemoral bypass grafting. Presented at 
Twenty-second Annual Spring Meeting of the American 
College of Surgeons, Washington DC, April 16, 1994. 
69. Davies AH, Ramaraldaa P, Collin J, Morris PJ. Recent 
changes in the treatment of aortoiliac occlusive disease by
the Oxford Regional Vascular Service. Br J Surg 1990;77: 
1129-31. 
70. Martin EC. Percutaneous therapy in the management of
aortoiliac disease. Semin Vasc Surg 1994;7:17-27. 
71. Vallance R. How does lower limb balloon angioplasty affect 
vascular surgical practice? J Intervent Radiol 1991 ;6:5-9. 
72. Stanley JC, Barnes RW, Ernst CB, etal. Vascular surgery in 
the United States: Workforce issues. Report of the Society 
for Vascular Surgery and the International Society for Car- 
diovascular Surgery, North American Chapter, Committee 
on Workforce Issues. J Vasc Surg 1996;23:172-81. 
73. Rholl KS, vanBreda A. Percutaneous intervention for aor- 
toiliac disease. In: Strandness DE, van Breda A, editors. 
Vascular diseases: surgical and interventional therapy. New 
York: Churchill Livingstone Inc, 1994:433-66. 
74. Rutherford RB, Becker GI. Standards for evaluating and 
reporting the results of surgical and percutaneous therapy 
for peripheral rterial disease. J Vasc Intervent Radiol 1991; 
2:]69-74. 
75. Johnston KW, Rae H, Hoss-Johnston SA, et ai. Five-year 
results of a prospective study of percutaneous transluminal 
angioplasty. Ann Surg 1987;206:404-13. 
76. Johnston KW. Iliac arteries: reanalysis of results of balloon 
angioplasty. Radiology 1993;186:207-12. 
77. Wilson SE, Wolf GL, Cross AP. Percutaneous translmninal 
angioplasty versus operation for peripheral arteriosclerosis: 
report of a prospective randomized trial in a selected group 
ofparients. J Vasc Surg 1989;9:1-9. 
78. Holm J, Arfvidsson B, Jivegad L, et al. Chronic lower limb 
ischemia. A prospective randomized controlled study com- 
paring the l-year results of vascular surgery and percutane- 
ous transluminai ngioplasty (P~A) Eur J Vasc Surg 1991;5: 
517-22. 
79. Standards of Practice Committee of the Society of Cardio- 
vascular and Interventional Radiology. Guidelines for percu- 
taneous transluminal ngioplasty. Radiology 1990;177:619- 
23. 
80. Brewster DC, Cambria RP, Darling RC, et al. Long-term 
results of combined iliac balloon angioplasty and distal sur- 
gical revascularization. A n Surg 1989;210:324-31. 
81. Brewster DC. Donor iliac PTA versus inflow bypass for iliac 
artery disease in patients requiting distal bypass: is PTA 
enough and is it durable? In: Veith FJ, editor. Current 
critical problems in vascular surgery. Vol 6. St Louis: Quality 
Medical PuNishing, Inc, 1994:225-33. 
82. Brewster DC. The role of angioplasty o improve inflow for 
infrainguinal bypasses. Eur J Vasc Surg 1995;9:262-6. 
83. Becker GJ. Intravascular stents: general principles and status 
of lower extremity arterial applications. Circulation 1991; 
83(suppl I):L22-36. 
84. Rees CR, Palmaz JC, Garcia O, et al. Angioplasty and stent- 
ing of completely occluded iliac arteries. Radiology 1989; 
172:953-9. 
85. Gunther RW, Vorwerk D, Bohndorf K, et al. Iliac and 
femoral artery stenoses and occlusions: treatment with ntra- 
vascular stents. Radiology 1989;172:725-30. 
86. Johnston KW. Balloon angioplasty and stents: their place in 
treating iliac, femoral, and popliteal occlusive disease. Amer- 
ican College of Surgeons Postgraduate course in Vascular 
Surgery, New Orleans, LA, October 1995. 
87. Palmaz JC, Laborde JC, Rivera FJ, etal. Stenting of the iliac 
arteries with the Palmaz stent: experience from a muir]center 
trial. Cardiovasc Intervent Radiol 1992;15:291-7. 
88. Richter GL, Roeren TM, Noeldge G, etal. Initial long-term 
results of a randomized 5-year study: iliac stent. Vasa 1992; 
35(suppl):192-3. 
89. Richter GM, Roeren T, Brado M, Noeldge G. Further 
update of the randomized trial: lilac stent placement versus 
PTA-morphology, clinical success rates, and failure analysis. 
J Vasc Intervent Radiol 1993;4:30. 
90. Porter IM. Endovascular terial intervention: expression of 
concern. J Vasc Surg 1995;21:995-7. 
JOURNAL OF VASCULAR SURGERY 
378 Brewster February 1997 
91. Black AJR, Roubin GS, Sutor C, et al. Comparative costs of 
percutaneous transluminal coronary angioplasty and coro- 
nary artery bypass grafting in multivessel coronary artery 
disease. Am J Cardiol 1988;62:809-11. 
92. Matin ML, Veith FJ, Cynamon J, et al. Initial experience 
with transluminally placed endovascular g afts for the treat- 
ment of complex vascular lesions. Ann Surg 1995;222:449- 
69. 
93. Dacey LJ, Dow RW, McDaniel MD, et al. Cost-effectiveness 
of intra-arterial thrombolytic therapy. Arch Surg 1988;123: 
1218-23. 
94. Ouriel K, Kolassa M, DeWeese JA, Green RM. Economic 
implications of thrombolysis or operation as the initial treat- 
ment modality in acute peripheral rterial occlusion. Surgery 
1995;118:810-4. 
95. Blaisdell FW, Hall AD. Axillary-femoral artery bypass for 
lower extremity ischemia. Surgery 1963;54:563-8. 
96. Vetto RM. The treatment of unilateral i iac artery obstruc- 
tion with a transabdominal, subcutaneous femoro-femoral 
graft. Surgery 1962;52:342-5. 
97. Mannick JA, Nabseth DC. Axillofemoral bypass graft: a safe 
alternative to aortoiliac reconstruction. N Engl J Med 1968; 
278:460-6. 
98. Parsonnet V, Alpert J, BriefDK. Femoro-femoral and axillo- 
femoral grafts: compromise or preference. Surgery 1970;67: 
26-33. 
99. Davis RC, O'Hara ET, Mannick JA, et al. Broadened indi- 
cations for femoro-femoral grafts. Surgery 1972;72:990-4. 
100. Johnson WC, LoGerfo FW, Vollman RW, et al. Is axillo- 
bilateral femoral graft an effective substitute for aortic-bilat- 
eral iliac/femoral graft? An analysis of ten years experience. 
Ann Surg 1977;186:123-9. 
101. Eugene J, Goldstone J, Moore WS. Fifteen year experience 
with subcutaneous bypass grafts for lower extremity isch- 
emia. Ann Surg 1977;186:177-83. 
102. Ray LI, O'Connor JB, Davis CC, et al. Axillofemoral bypass: 
a critical reappraisal of its role in the management of aor- 
toiliac disease. Surgery 1979;138:117-28. 
103. BriefDK, Brener BJ, Alpert J, ParsonnetV. Crossover femo- 
rofemoral grafts followed up five years or more. Arch Surg 
1975;110:1294-9. 
104. Couch NP, Clowes AW, Whittemore AD, et al. The iliac- 
origin arterial graft: a useful alternative for iliac occlusive 
disease. Surgery 1985;97:83-7. 
105. Piotrowsld JJ, Pearce WH, Jones DN, et al. Aortobifemoral 
bypass: the operation of choice for unilateral iliac occlusion? 
J Vase Surg 1988;8:211-8. 
106. Harrington ME, Harrington EB. Options in the manage- 
ment of unilateral i iac occlusive disease. S min Vase Surg 
1994;7:45-53. 
107. Darling RC III, Leather PEP, Chang BB, et al. Is the iliac 
artery a suitable inflow conduit for iliofemoral occlusive 
disease: an analysis of 514 aortoiliac reconstructions. J Vasc 
Surg 1993;17:15-22. 
108. Passman MA, Taylor LM Jr, Moneta GL, et al. Comparison 
of axillofemoral and aortofemoral bypass for aortoiliac oc- 
clusive disease. J Vase Surg (in press). 
109. Rutherford RB, Part A, Pearce WH. Extra-anatomic bypass: 
a closer view. J Vase Surg 1987;6:437-46. 
110. Moore WS, Hall AD, Blaisdell FW. Late results of axillary- 
femoral bypass grafting. Am J Surg 1971;122:148-54. 
111. Mannick JA, Williams LE, Nabseth DC. The late results of 
axillofemoral grafts. Surgery 1970;68:1038-43. 
112. Livesay JT, Atldnson JB, Baker JD, et al. Late results of 
extra-anatomic bypass. Arch Surg 1979;114:1260-7. 
113. Mason RA, Smirnov VB, Newton GB, Giron B. Alternative 
procedures to aorto-bifemoral bypass grafting. J Cardiovasc 
Surg 1989;30:192-7. 
114. Hepp W, de Jonge K, Pallua N. The late results following 
extra-anatomic bypass procedure for chronic aortoiliac oc- 
clusive disease. J Cardiovasc Surg 1988;29:181-4. 
115. Donaldson MC, Louras JC, Buckman CA. Axillofemoral 
bypass: a tool with a limited role. J Vase Surg 1986;3:757- 
63. 
116. Harrington ME, Harrington EB, Haimov M, et al. Axil- 
lofemoral bypass: compromised bypass for compromised 
patients. J Vase Surg 1994;20:195-201. 
117. Kalman PG, Hosang M, Cina C, et al. Current indications 
for axillounifemoral and axillobifemoral bypass grafts. J Vase 
Surg 1987;5:828-32. 
118. Schneider JR, McDaniel MD, Walsh DB, et al. Axillofemo- 
ral bypass: outcome and hemodynamic results in high-risk 
patients. J Vase Surg 1992;15:952-63. 
119. EI-Massry S, Saad E, Sanvage LR, et al. Axillofemoral bypass 
with externally supported, knitted Dacron grafts: a fol- 
low-up through twelve years. J Vase Surg 1993;17:107-15. 
120. Harris EJ Jr, Taylor LM, McConnell DB, et al. Clinical 
results of axillo-bifemoral bypass using externally supported 
polytetrafluoroethylene. J Vase Surg 1990;12:416-21. 
121. Blaisdell FW. Axillofemoral bypass: long-term results. In: 
Yao JST, Pearce WH, editors. Long-term results in vascular 
surgery. Norwalk, CT: Appleton and Lange, 1993:395-9. 
122. Taylor LM, Freimanis IE, Edwards JM, Porter JM. Extra- 
peritoneal iliac endarterectomy in the treatment of multi- 
level lower extremity arterial occlusive disease. Am J Surg 
1986;152:34-9. 
123. Vitale GF, Inahara T. Extraperitoneal endarterectomy for
iliofemoral occlusive disease. J Vasc Surg 1990;12:409-15. 
124. Dick LS, BriefDK, Alpert J, et al. A 12-year experience with 
femorofemoral crossover grafts. Arch Surg 1980;115:1359- 
65. 
125. Brener BJ, BriefDK, Alpert J, et al. Femorofemoral bypass: a 
twenty-five year experience. In: Yao JST, Pearce WH, edi- 
tors. Long-term results in vascular surgery. Norwalk, CT: 
Appleton and Lange, 1993:385-93. 
126. Kalman PG, Hosang M, Johnston KW, Walker PM. The 
current role for femoro-femoral bypass. J Vasc Surg 1987;6: 
71-6. 
127. Harrington ME, Harrington EB, Haimov M, et al. Iliofem- 
oral versus femoro-femoral bypass: the case for an individu- 
alized approach. J Vase Surg 1992;16:841-54. 
128. Kalman PG, Hosang M, Johnston KW, Walker PM. Unilat- 
eral iliac disease: the role of iliofemoral bypass. J Vasc Surg 
1987;6:139-43. 
129. Perler BA, Burdick JF, Williams GM. Femoro-femoral or
iliofemoral bypass for unilateral iliac reconstruction. Am J 
Surg 1991;161:426-30. 
130. Ng RLH, Gillies TE, Davies AH, et al. Iliofemoral versus 
femorofemoral bypass: a 6-year audit. Br J Surg 1992;79: 
1011-3. 
131. Brener BJ, Brief DK, Alpert J, et al. What is the optimal 
treatment of unilateral i iac disease? In: Veith FJ, editors. 
Current critical problems in vascular surgery. Vol 5. St Lou- 
is: Quality Medical Publishing, Inc, 1993:316-21. 
132. Association Universitaire de Recherche n Chimgie, Ricco 
J-B. Unilateral iliac artery occlusive disease: a randomized 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 2 Brewster 379 
multicenter t ial examining direct revascularization versus 
crossover bypass. Ann Vase Surg 1992;6:209-19. 
133. Schneider JR, Besso SR, Walsh DB, et al. Femorofemoral 
versus aortobifemoral bypass: outcome and hemodynamic 
results. J Vase Surg 1994;19:43-57. 
134. Levinson SA, Levinson HJ, Halloran LG, et al. Limited 
indications for unilateral aortofemoral or iliofemoral vascu- 
lar grafts. Arch Surg 1973;107:791-6. 
135. Kram HB, Gupta SK, Veith FJ, Wengerter KR. Unilateral 
aortofemoral bypass: a safe nd effective option for the treat- 
ment for unilateral limb-threatening ischemia. Am J Surg 
1991;162:155-8. 
136. Louw JH. Splenic-to-femoral and axillary-to-femoral bypass 
grafts in diffuse atherosclerotic o clusive disease. Lancet 
1963;29:1401-2. 
137. Sanvage LR, Wood SJ. Unilateral axillary bilateral femoral 
bifurcation graft: a procedure for the poor risk patient with 
aortoiliac disease. Surgery 1966;60:573-7. 
138. Schultz GA, Sanvage LR, Mathisen SR, et al. A five-to 
seven-year experience with externally supported Dacron 
prostheses in axillofemoral and femoropopliteal bypass. Ann 
Vasc Surg 1986;1:214-23. 
139. Taylor LM Jr, Moneta GL, McConnell D, et al. Axillofemo- 
ral grafting with externally supported polytetrafluoroethyl- 
ene. Arch Surg 1994;129:588-95. 
140. Wittens CHA, Van Houtte HJKP, Van Urk H. European 
prospective randomized multicentre axillo-bifemoral trial. 
Eur J Vase Surg 1992;6:115-23. 
141. Kenney DA, Sanvage LR, Wood SJ, et al. Comparison of 
noncrimped, externally supported (EXS) and crimped, non- 
supported Dacron prostheses for axillofemoral and above- 
knee femoropopliteal bypass. Surgery 1982;92:931-46. 
142. Cavallaro A, Sciacca V, DiMarzo L, et al. The effect of body 
weight compression on axillo-femoral by-pass patency. 
J Cardiovasc Surg 1988;29:476-9. 
143. Jarowenko MV, Buchbinder D, Shah DM. Effect of external 
pressure on axillofemoral bypass grafts. Ann Surg 1981;193: 
274-6. 
144. Burrell MJ, Wheeler JR, Gregory RT, et al. Axillofemoral 
bypass: a ten-year review. Ann Surg 1982;195:796-9. 
145. Christenson JT, Broome A, Norgren L, Eklof B. The late 
results after axillo-femoral bypass grafts in patients with leg 
ischemia. J Cardiovasc Surg 1986;27:131-5. 
146. Moore WS. In discussion of Harris EJ Jr, Taylor LM Jr, 
McConnell DB, et al. Clinical results of axillobifemoral 
bypass using externally supported polytetrafluoroethylene. J 
Vasc Surg 1990;12:416-21. 
147. Calligaro KD, Ascer E, Veith FJ, et al. Unsuspected inflow 
disease in candidates for axillofemoral bypass operations: a 
prospective study. J Vasc Surg 1990;11:832-7. 
148. Taylor LM Jr, Park TC, Edwards JM, et al. Acute disruption 
of polytetrafluorethylene grafts adjacent to axillary anasto- 
moses: a complication ofaxillofemoral grafting. J Vasc Surg 
1994;20:520-8. 
149. Rutnerford RB, Rainer W. A modified technique for per- 
forming axillobifemoral bypass grafting. J Vasc Surg 1989; 
10:468-9. 
150. Ward RE, Holcroft JW, Conti S, Blaisdell FW. New con- 
cepts in the use of axillofemoral bypass grafts. Arch Surg 
1983;118:573-6. 
151. Schneider JR, Golan JF. The role ofextraanatomic bypass in 
the management of bilateral aortoiliac occlusive disease. 
Semin Vasc Surg 1994;7:35-44. 
152. Bunt TJ. Aortic reconstruction vsextraanatomic bypass and 
angioplasty. Arch Surg 1986;121:1166-70. 
Submitted Feb. 27, 1996; accepted May 20, 1996. 
